EUVIMEDEUVIMED entdecken
CrossrefInfokarte

The global landscape of lean metabolic dysfunction-associated steatotic liver disease: insight from Asia and the West

Hery Djagat Purnomo, Randy Adiwinata, Cecilia Oktaria Permatadewi, Hesti Triwahyu Hutami, Didik Indiarso

Frontiers in Gastroenterology · 2025-12-02 · 4

DOI: 10.3389/fgstr.2025.1699508 ↗
AbstractBibliografische Angaben

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as a leading global cause of chronic liver disease, affecting 25–30% of the population. While MASLD is traditionally associated with obesity, lean MASLD—a subset characterized by hepatic steatosis and metabolic dysfunction in individuals with a normal body mass index (BMI)—is increasingly recognized as a distinct clinical entity. Lean MASLD accounts for approximately 5.1% of the global population and is more prevalent in Asia, where genetic predispositions such as PNPLA3 and TM6SF2 polymorphisms, visceral obesity, and high-carbohydrate dietary patterns are key risk factors. Lean MASLD is also associated with significant liver and non-liver complications, as well as increased all-cause mortality risk. Therefore, lean MASLD may pose a significant challenge for practitioners.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →